AXT, Inc. 2023 Q3 Form 10-Q Summary
Business Context and Reporting Period
AXT develops and manufactures compound and single-element semiconductor substrates, including indium phosphide, gallium arsenide and germanium wafers, and sells related raw materials such as purified gallium and pBN crucibles. Manufacturing is conducted through subsidiaries and joint ventures in China. The filing covers the quarter and nine months ended September 30, 2023; results are unaudited and presented under U.S. GAAP.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $17.4 million | $35.2 million | $55.4 million | $114.3 million |
| Gross profit | $1.9 million | $14.8 million | $8.7 million | $43.5 million |
| Gross margin | 10.7% | 42.0% | 15.7% | 38.1% |
| Operating income (loss) | $(6.7) million | $4.6 million | $(18.0) million | $13.6 million |
| Net income (loss) attributable to AXT | $(5.8) million | $5.8 million | $(14.3) million | $14.5 million |
| EPS attributable to AXT | $(0.14) | $0.14 basic | $(0.34) | $0.34 basic |
| Operating cash flow | Not separately reported for the quarter | Not separately reported for the quarter | $2.0 million | $(9.3) million |
Q3 substrate revenue was $10.4 million, down 61.3%, while raw-materials and other revenue was $7.0 million, down 16.1%. For the nine-month period, substrate revenue declined 61.3% to $34.9 million and raw-materials revenue declined 14.8% to $20.5 million.
At September 30, 2023, cash and cash equivalents were $28.5 million, restricted cash was $10.8 million and short-term investments were $4.3 million. Total cash, restricted cash and investments were $43.6 million, compared with $52.8 million at December 31, 2022. Bank loans were $45.8 million, all classified as current. Total assets were $342.2 million and total stockholders’ equity was $227.4 million.
Material Changes Versus the Prior Comparable Period
- Revenue fell 50.6% in Q3 and 51.6% for the first nine months, primarily because of weaker demand for InP, GaAs and Ge substrates in data-center, consumer, telecommunications and other applications.
- Gross margin contracted sharply because of lower factory utilization and under-absorbed overhead, unfavorable product mix and lower raw-material margins while higher-cost inventory was sold.
- Operating expenses declined 15.2% in Q3 and 10.9% for the nine-month period, but not enough to offset the revenue and gross-profit decline.
- Equity income from unconsolidated joint ventures decreased to $0.4 million in Q3 and $2.3 million for nine months, versus $2.0 million and $5.3 million, respectively, reflecting lower raw-material sales and a JiYa impairment.
- Operating cash flow improved to $2.0 million from an outflow of $9.3 million, primarily due to working-capital changes and dividends received from equity-method investments.
- Capital expenditures declined to $11.2 million from $28.8 million. Construction in progress totaled $42.1 million, including $35.4 million related to new Dingxing and Kazuo facilities.
- Revenue concentration declined: no customer represented at least 10% of Q3 or nine-month revenue, compared with Landmark representing 18% of Q3 2022 and 14% of nine-month 2022 revenue.
Outlook, Commentary, Risks and Unusual Items
Management stated that it believes available cash and investments are adequate for operating needs and capital expenditures over the next twelve months. The filing does not provide clear numerical revenue or earnings guidance. Management expects demand cycles to continue and notes that lower sales could accelerate cash usage and require additional capital.
- China adopted export controls on gallium- and germanium-related materials effective August 1, 2023. Tongmei received initial permits to ship certain GaAs and germanium substrates, but continued permits and broader customer coverage are not assured.
- Tongmei’s proposed STAR Market IPO remains subject to review and approval by the CSRC and other authorities. Investors holding approximately $49 million of redeemable Tongmei interests may require redemption if the IPO fails specified conditions or is cancelled.
- Q2 2023 included a $754,000 impairment charge recorded by JiYa. AXT also recognized approximately $575,000 from selling 15% of Jia Mei and $383,000 from remeasuring the retained 10% interest.
- Government grants for technological innovation and job creation contributed $1.9 million to other income for the first nine months, compared with $0.2 million in the prior period.
- U.S. tariffs on China-made wafer imports totaled approximately $768,000 during the first nine months. The company identifies tariffs, trade restrictions, foreign exchange, Chinese regulation, environmental shutdowns, customer qualification, product yields and semiconductor-cycle volatility as material risks.
- In October and November 2023, the company obtained $3.5 million of new one-year unsecured bank loans at rates of 3.45% to 3.8% and repaid $2.7 million of existing loans.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter. No material adverse legal proceedings were disclosed.
Most Important Facts for Investors to Verify
- Whether semiconductor demand, particularly for InP, GaAs and Ge substrates, is recovering sufficiently to improve utilization and restore gross margins.
- The status of China export permits for GaAs and germanium substrates and the effect of export controls on customer shipments.
- The timeline and approval prospects for the Tongmei STAR Market IPO and the potential $49 million redemption obligation.
- Whether $43.6 million of cash, restricted cash and investments is sufficient given $45.8 million of current bank loans, ongoing capital spending and continuing operating losses.
- The recoverability of $86.4 million of inventory, including $24.7 million of excess and obsolete inventory reserves, and the potential for additional write-downs.
- Progress and remaining costs associated with the Dingxing and Kazuo facilities and customer qualification of relocated production.
- The sustainability of dividends and earnings from China-based equity-method investments, including exposure to impairment and regulatory risks.